combination therapy – Page 5 – Communicable Diseases Research

Combination anti-HIV antibodies provide sustained virological suppression

Research

Published on 2022-06-012022-10-05
Journal: Nature [Category] 바이오마커, 임상, 치료제,

Optimal Drug Regimen and Combined Drug Therapy and Its Efficacy in the Treatment of COVID-19: A Within-Host Modeling Study

최적의 약물 요법과 복합 약물 요법과 COVID-19 치료의 효능: 숙주 내 모델링 연구

Article

Published on 2022-05-192022-09-11
Journal: Acta biotheoretica [Category] COVID19(2023년), SARS, 치료제,

[키워드] Administered administration Arbidol average basic reproduction number Cell Combination combination therapies combination therapy Combined Comparative Comparative effectiveness study COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 pathogenesis death drug Drug interventions drugs Effectiveness Efficacy help include infected cells infection-related mortality Inflammatory mediators interferon Intervention life-threatening Lopinavir Lopinavir/ritonavir mathematical medical intervention modeling number of infected Optimal control problem Optimal drug Regimen physician reduce regimen Remdesivir Ritonavir significantly Stage susceptible cell Treatment treatment of COVID-19 Viral load were used
[DOI] 10.1007/s10441-022-09440-8 PMC 바로가기 [Article Type] Article

Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics

COVID-19 햄스터 모델에서 덱사메타손 및 항체 치료의 주요 이점, 단일 세포 전사체로 밝혀짐

Article

Published on 2022-05-042022-09-11
Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, 치료법, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Analysis analyzed Anti-inflammatory anti-inflammatory effect anti-inflammatory properties anti-inflammatory property anti-SARS-CoV-2 antibody Anti-viral anti-viral effect anti-viral effects antibodies antibody antibody treatment benefit Cell combination therapy coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 treatment Dexamethasone disease drugs Effect effective Efficacy exhibited hamster host responses immune responses Immunity Infection Inflammatory inflammatory cell lung Lungs mechanisms monoclonal antibody monoclonal antibody therapy Neutrophils potential mechanism prevented pulmonary pulmonary immune response recruitment respiratory SARS-CoV-2 scRNA-seq severe disease single-cell Standard-of-care subpopulation synergistic synergistic effects therapeutic option therapeutic options Therapies therapy transcriptomic transcriptomics Treatment Vaccine vaccine efficacy Vaccine hesitancy variants Viral viral burden was reduced
[DOI] 10.1016/j.ymthe.2022.03.014 PMC 바로가기 [Article Type] Article

Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study

저산소증 성인 COVID-19에 대한 바리시티닙, 렘데시비르 및 덱사메타손 조합의 효능: 후향적 연구

Article

Published on 2022-05-012022-09-11
Journal: Respiratory medicine and research [Category] COVID19(2023년), SARS, 변종, 치료제,

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

Research article

Published on 2022-04-212022-10-05
Journal: EClinicalMedicine [Category] 바이오마커, 임상,

[키워드] 28-day mortality 95% CI anti-SARS-CoV-2 antibody antibody Antibody Response assessment assigned authority benefit clearance combination therapy Coronavirus disease 2019 Coronavirus disease-19 COVACTA COVID-19 Department development died discharged double-blind Effect Efficacy and safety Europe finding funding Future Hoffmann-La Roche hospital hospital discharge hospitalised Host immune response Human impair IMPROVE Infection intensive care interleukin-6 intravenous tocilizumab investigated Mortality Nasopharyngeal swab neutralising North America occurred office other treatments Patient patient selection patients with COVID-19 Placebo placebo-controlled trial polymerase chain positive test result Potential biomarker randomised randomised controlled trial Randomly respiratory response SARS-CoV-2 SARS-CoV-2 viral load Secretary serum serum samples severe acute respiratory syndrome coronavirus-2 tested Tocilizumab Treatment viral clearance Viral load with COVID-19
[DOI] 10.1016/j.eclinm.2022.101409 [Article Type] Research article

The effectiveness of dexamethasone as a combination therapy for COVID-19

Review

Published on 2022-04-132023-07-11
Journal: Acta pharmaceutica (Zagreb, Croatia) [Category] COVID19(2023년),

[키워드] acute respiratory distress syndrome combination therapy Coronavirus disease 2019 Dexamethasone glucocorticosteroids immunosuppressive. SARS-CoV-2
[DOI] 10.2478/acph-2022-0030 [Article Type] Review

Pre-erythrocytic Activity of M5717 in Monotherapy and Combination in Preclinical Plasmodium Infection Models

Article

Published on 2022-04-082024-08-28
Journal: ACS Infectious Diseases [Category] 말라리아,

[키워드] combination therapy Drug discovery liver stage infection M5717 malaria pyronaridine.

Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema

Multicenter Study

Published on 2022-04-012023-07-07
Journal: Acta Diabetologica [Category] COVID19(2023년),

[키워드] aflibercept combination therapy Dexamethasone Diabetic macular edema.
[DOI] 10.1007/s00592-021-01824-5 PMC 바로가기 [Article Type] Multicenter Study

Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection

Review

Published on 2022-04-012022-10-04
Journal: Infection [Category] COVID19(2023년), SARS, 신약개발,

[키워드] age antiviral agent Antiviral agents Baricitinib cellular cellular signaling pathway Combination combination therapy Coronavirus disease 2019 COVID-19 COVID-19 infection Cytokine storm disease-specific treatments Drug-drug interactions dysregulated immune response Effect Effectiveness form Google Hospitalized hospitalized patient Infection Inflammatory response inhibitor Jak Janus kinase Janus kinase pathway lack moderate modulate outcome pandemic pathway Pediatric patient positive pro-inflammatory problems repurposing Repurposing drug therapy resulting severe COVID-19 severe COVID-19 patient severe SARS-CoV-2 severity of COVID-19 shown Standard of care subcellular synergistic therapeutic Therapeutic approach therapy Treatment virus entry
[DOI] 10.1007/s15010-021-01730-6 PMC 바로가기 [Article Type] Review

MMV020275 and MMV020490, promising compounds from malaria box for the treatment of equine piroplasmosis

Article

Published on 2022-03-312024-09-10
Journal: Ticks Tick Borne Dis [Category] 말라리아,

[키워드] Babesia microti combination therapy Drug discovery malaria box MMV020275 MMV020490 Theileria equi.
PMC 바로가기